A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder

Andrew W. Goddard, Waqar Mahmud, Carla Medlock, Yong Wook Shin, Anantha Shekhar

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Open-label quetiapine coadministration with SSRI therapy, in a diagnostically mixed sample of comorbid anxiety patients, offered additional anxiolytic benefit. Therefore, we designed the following controlled trial to confirm these findings in a comorbid, SSRI-resistant, panic disorder (PD) patient sample. Methods: This was a single-site, double-blind, placebo-controlled (PLAC), randomized, parallel group (2 groups), 8-week, quetiapine extended release (XR) coadministration trial. SSRI resistance was determined either historically or prospectively. Patients were randomized if they remained moderately ill (CGI-S score≥4). Change in the PDSS scale total score was the primary efficacy outcome measure. Responders were identified as those with a≥50% decrease from their baseline PDSS score. In the early weeks of therapy, XR was flexibly and gradually titrated from 50 to 400mg/day. Results: 43 patients were screened in total, and 26 of these were randomized and evaluable. 21 patients (78% of the randomized group) completed the trial (10 XR; 11 PLAC). The endpoint quetiapine XR mean daily dose±SD was 150±106mg. While, in the sample as a whole, there was improvement in PDSS scores across the 8-week trial (ANOVA main effect of time, F=10.9, df 8,192, p8,192, p=0.61). There was no between-group difference in responder frequency at endpoint. Conclusions: This proof-of-concept RCT did not support the efficacy of this treatment strategy for SSRI-resistant PD. Quetiapine XR was generally well-tolerated. Important limitations were the small sample size, and the relatively low average dose of quetiapine XR used. ClinicalTrials.gov ID#: NCT00619892

Original languageEnglish (US)
Article number26
JournalAnnals of General Psychiatry
Volume14
Issue number1
DOIs
StatePublished - Sep 15 2015

Fingerprint

Panic Disorder
Placebos
Therapeutics
Anti-Anxiety Agents
Secondary Prevention
Sample Size
Analysis of Variance
Anxiety
Outcome Assessment (Health Care)
Quetiapine Fumarate

Keywords

  • Atypical neuroleptics
  • Augmentation treatment
  • Panic disorder
  • Quetiapine XR

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder. / Goddard, Andrew W.; Mahmud, Waqar; Medlock, Carla; Shin, Yong Wook; Shekhar, Anantha.

In: Annals of General Psychiatry, Vol. 14, No. 1, 26, 15.09.2015.

Research output: Contribution to journalArticle

Goddard, Andrew W. ; Mahmud, Waqar ; Medlock, Carla ; Shin, Yong Wook ; Shekhar, Anantha. / A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder. In: Annals of General Psychiatry. 2015 ; Vol. 14, No. 1.
@article{2a639c18f92640d4a8fb7da245ccbdbd,
title = "A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder",
abstract = "Background: Open-label quetiapine coadministration with SSRI therapy, in a diagnostically mixed sample of comorbid anxiety patients, offered additional anxiolytic benefit. Therefore, we designed the following controlled trial to confirm these findings in a comorbid, SSRI-resistant, panic disorder (PD) patient sample. Methods: This was a single-site, double-blind, placebo-controlled (PLAC), randomized, parallel group (2 groups), 8-week, quetiapine extended release (XR) coadministration trial. SSRI resistance was determined either historically or prospectively. Patients were randomized if they remained moderately ill (CGI-S score≥4). Change in the PDSS scale total score was the primary efficacy outcome measure. Responders were identified as those with a≥50{\%} decrease from their baseline PDSS score. In the early weeks of therapy, XR was flexibly and gradually titrated from 50 to 400mg/day. Results: 43 patients were screened in total, and 26 of these were randomized and evaluable. 21 patients (78{\%} of the randomized group) completed the trial (10 XR; 11 PLAC). The endpoint quetiapine XR mean daily dose±SD was 150±106mg. While, in the sample as a whole, there was improvement in PDSS scores across the 8-week trial (ANOVA main effect of time, F=10.9, df 8,192, p8,192, p=0.61). There was no between-group difference in responder frequency at endpoint. Conclusions: This proof-of-concept RCT did not support the efficacy of this treatment strategy for SSRI-resistant PD. Quetiapine XR was generally well-tolerated. Important limitations were the small sample size, and the relatively low average dose of quetiapine XR used. ClinicalTrials.gov ID#: NCT00619892",
keywords = "Atypical neuroleptics, Augmentation treatment, Panic disorder, Quetiapine XR",
author = "Goddard, {Andrew W.} and Waqar Mahmud and Carla Medlock and Shin, {Yong Wook} and Anantha Shekhar",
year = "2015",
month = "9",
day = "15",
doi = "10.1186/s12991-015-0064-0",
language = "English (US)",
volume = "14",
journal = "Annals of General Psychiatry",
issn = "1744-859X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder

AU - Goddard, Andrew W.

AU - Mahmud, Waqar

AU - Medlock, Carla

AU - Shin, Yong Wook

AU - Shekhar, Anantha

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Background: Open-label quetiapine coadministration with SSRI therapy, in a diagnostically mixed sample of comorbid anxiety patients, offered additional anxiolytic benefit. Therefore, we designed the following controlled trial to confirm these findings in a comorbid, SSRI-resistant, panic disorder (PD) patient sample. Methods: This was a single-site, double-blind, placebo-controlled (PLAC), randomized, parallel group (2 groups), 8-week, quetiapine extended release (XR) coadministration trial. SSRI resistance was determined either historically or prospectively. Patients were randomized if they remained moderately ill (CGI-S score≥4). Change in the PDSS scale total score was the primary efficacy outcome measure. Responders were identified as those with a≥50% decrease from their baseline PDSS score. In the early weeks of therapy, XR was flexibly and gradually titrated from 50 to 400mg/day. Results: 43 patients were screened in total, and 26 of these were randomized and evaluable. 21 patients (78% of the randomized group) completed the trial (10 XR; 11 PLAC). The endpoint quetiapine XR mean daily dose±SD was 150±106mg. While, in the sample as a whole, there was improvement in PDSS scores across the 8-week trial (ANOVA main effect of time, F=10.9, df 8,192, p8,192, p=0.61). There was no between-group difference in responder frequency at endpoint. Conclusions: This proof-of-concept RCT did not support the efficacy of this treatment strategy for SSRI-resistant PD. Quetiapine XR was generally well-tolerated. Important limitations were the small sample size, and the relatively low average dose of quetiapine XR used. ClinicalTrials.gov ID#: NCT00619892

AB - Background: Open-label quetiapine coadministration with SSRI therapy, in a diagnostically mixed sample of comorbid anxiety patients, offered additional anxiolytic benefit. Therefore, we designed the following controlled trial to confirm these findings in a comorbid, SSRI-resistant, panic disorder (PD) patient sample. Methods: This was a single-site, double-blind, placebo-controlled (PLAC), randomized, parallel group (2 groups), 8-week, quetiapine extended release (XR) coadministration trial. SSRI resistance was determined either historically or prospectively. Patients were randomized if they remained moderately ill (CGI-S score≥4). Change in the PDSS scale total score was the primary efficacy outcome measure. Responders were identified as those with a≥50% decrease from their baseline PDSS score. In the early weeks of therapy, XR was flexibly and gradually titrated from 50 to 400mg/day. Results: 43 patients were screened in total, and 26 of these were randomized and evaluable. 21 patients (78% of the randomized group) completed the trial (10 XR; 11 PLAC). The endpoint quetiapine XR mean daily dose±SD was 150±106mg. While, in the sample as a whole, there was improvement in PDSS scores across the 8-week trial (ANOVA main effect of time, F=10.9, df 8,192, p8,192, p=0.61). There was no between-group difference in responder frequency at endpoint. Conclusions: This proof-of-concept RCT did not support the efficacy of this treatment strategy for SSRI-resistant PD. Quetiapine XR was generally well-tolerated. Important limitations were the small sample size, and the relatively low average dose of quetiapine XR used. ClinicalTrials.gov ID#: NCT00619892

KW - Atypical neuroleptics

KW - Augmentation treatment

KW - Panic disorder

KW - Quetiapine XR

UR - http://www.scopus.com/inward/record.url?scp=84941551951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941551951&partnerID=8YFLogxK

U2 - 10.1186/s12991-015-0064-0

DO - 10.1186/s12991-015-0064-0

M3 - Article

AN - SCOPUS:84941551951

VL - 14

JO - Annals of General Psychiatry

JF - Annals of General Psychiatry

SN - 1744-859X

IS - 1

M1 - 26

ER -